The growth inhibitory effect of TAM on ERα+ breast cancer cells is attributed to the competitive inhibition of the binding of estrogen to ERα, resulting in the repression of estrogen responsive genes [6, 7]. This evidence concerns the gene ESR1 and breast carcinoma.